Pelthos Therapeutics Inc. PTHS
7.44 USD -0.59 (-7.35%)
Regular-session close
7.44 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
7.27 Day range 8.46
7.27 52-week range 34.68
- YTD
- -76.00%
- 1 year
- -78.55%
News
benzinga.com Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21 Piper Sandler analyst David Amsellem reiterates Pelthos Therapeutics (AMEX:PTHS) with a Overweight and lowers the price target from $48 to $21.
benzinga.com Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $59 Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $64 to $59.
seekingalpha.com Pelthos Therapeutics Inc. (PTHS) Q3 2026 Earnings Call Transcript Pelthos Therapeutics Inc. (PTHS) Q3 2026 Earnings Call Transcript
benzinga.com Pelthos Therapeutics Q3 2026 Earnings Call Transcript Pelthos Therapeutics (AMEX:PTHS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
zacks.com Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates Pelthos Therapeutics Inc. (PTHS) came out with a quarterly loss of $3.09 per share versus the Zacks Consensus Estimate of a loss of $2.83. This compares to a loss of $5.3 per share a year ago.benzinga.com Pelthos Therapeutics Q3 EPS $(2.04) Beats $(3.07) Estimate, Sales $15.395M Miss $17.605M Estimate Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(2.04) per share which beat the analyst consensus estimate of $(3.07) by 33.55 percent. This is a 61.51 percent increase over losses of…
globenewswire.com Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update Zelsuvmi ® net product revenue grew 114% to $15.2 million during the third quarter of 2026 from $7.1 million in the third quarter of 2025
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…benzinga.com Pelthos Therapeutics Strikes Business Combination Agreement With Castle Creek Biosciences; Shareholders Of Castle Creek Biosciences To Receive 5.2M Common Shares Of Pelthos Pelthos Therapeutics Inc. (NYSE:PTHS) ("Pelthos" or the "Company"), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, and Castle Creek
benzinga.com Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40 Lake Street analyst Thomas Flaten maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $50 to $40.
benzinga.com Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64 Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and lowers the price target from $66 to $64.
benzinga.com Pelthos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript Pelthos Therapeutics (AMEX:PTHS) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…benzinga.com Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.62) per share which missed the analyst consensus estimate of $(3.05) by 117.05 percent. This is a 23.05 percent decrease over losses…
benzinga.com Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company…
benzinga.com Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66 Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.
benzinga.com Pelthos Therapeutics Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 14, 2026 benzinga.com Pelthos Therapeutics Q1 EPS $(3.09) Beats $(3.81) Estimate, Sales $10.906M Beat $10.445M Estimate Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(3.09) per share which beat the analyst consensus estimate of $(3.81) by 18.9 percent. The company reported quarterly sales of $10.906…
benzinga.com Pelthos Therapeutics Appoints John M. Gay As CFO Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced John M. Gay has…
benzinga.com Pelthos Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Evaluating CT2000 As Potential Treatment For Eye Pain First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye diseaseCT2000 is a…
benzinga.com Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $62 Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $60 to $62.
benzinga.com HC Wainwright & Co. Reiterates Buy on Pelthos Therapeutics, Maintains $60 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Pelthos Therapeutics (AMEX:PTHS) with a Buy and maintains $60 price target.
benzinga.com Earnings Scheduled For March 19, 2026 benzinga.com Pelthos Therapeutics Q4 EPS $(6.87) Misses $(4.13) Estimate, Sales $9.389M Beat $9.090M Estimate Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.87) per share which missed the analyst consensus estimate of $(4.13) by 66.34 percent. This is a 115.36 percent decrease over losses…
benzinga.com This Jazz Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday Top analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, initiations. See what they think of JAZZ stock.benzinga.com Piper Sandler Initiates Coverage On Pelthos Therapeutics with Overweight Rating, Announces Price Target of $48 Piper Sandler analyst David Amsellem initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Overweight rating and announces Price Target of $48.
benzinga.com Roth Capital Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $55 Roth Capital analyst Jonathan Aschoff maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $57 to $55.
benzinga.com Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $60 Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $57 to $60.
benzinga.com Pelthos Therapeutics Acquires Xeglyze For $1.8M From Hatchtech Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has…
benzinga.com On Dec 23, Pelthos Therapeutics Enters Asset Purchase Agreement With Hatchtech; Hatchtech Sells Rights To Xeglyze Product To Co. For $1.8M On December 23, 2025, Pelthos Therapeutics Inc., a Nevada corporation (the "Company") entered into an Asset Purchase Agreement (the "Asset Purchase Agreement") with Hatchtech Pty Ltd ACN 098 559 409,…
benzinga.com Pelthos Signs First Big Deal to Expand Access to Its At-Home Treatment for Molluscum Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has signed its…
benzinga.com Lake Street Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $50 Lake Street analyst Thomas Flaten initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $50.
benzinga.com This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday benzinga.com HC Wainwright & Co. Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $60 HC Wainwright & Co. analyst Brandon Folkes initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $60.
benzinga.com Roth Capital Initiates Coverage On Pelthos Therapeutics with Buy Rating, Announces Price Target of $57 Roth Capital analyst Jonathan Aschoff initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Buy rating and announces Price Target of $57.
benzinga.com Oppenheimer Reiterates Outperform on Pelthos Therapeutics, Raises Price Target to $57 Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $50 to $57.
benzinga.com Pelthos Therapeutics Q3 EPS $(5.30) Misses $(0.55) Estimate, Sales $7.406M Beat $4.380M Estimate Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the analyst consensus estimate of $(0.55) by 863.64 percent. The company reported quarterly sales of…
benzinga.com Earnings Scheduled For November 13, 2025
benzinga.com EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Oppenheimer Initiates Coverage On Pelthos Therapeutics with Outperform Rating, Announces Price Target of $50 Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces Price Target of $50.
benzinga.com Pelthos Therapeutics Q2 EPS $(5.38) Beats $(6.26) Estimate Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.38) per share which beat the analyst consensus estimate of $(6.26) by 14.06 percent. This is a 75.24 percent decrease over losses of…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.benzinga.com Ligand Pharm's Partner Pelthos Therapeutics Commercially Launches ZELSUVMI Topical Gel 10.3%, FDA-Approved At-Home Treatment For Molluscum Contagiosum Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket
